Caplin Steriles gets USFDA approval for Neostigmine Methylsulfate Injection

Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT) Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Neostigmine Methylsulfate Injection USP, 5 mg/10 mL (0.5 mg/mL) and 10 mg/10 mL (1 mg/mL), Multiple-Dose vial presentations, a generic therapeutic equivalent version of (RLD), BLOXIVERZ Injection, of Exela Pharma Sciences, LLC, USA.

Neostigmine Methylsulfate Injection is a cholinesterase inhibitor and is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery. According to IQVIATM (IMS Health), Neostigmine Methylsulfate Injection had US sales data of approximately $20 million for the 12-month period ending Dec 2020.

Shares of CAPLIN POINT LABORATORIES LTD. was last trading in BSE at Rs.503.5 as compared to the previous close of Rs. 491.5. The total number of shares traded during the day was 49075 in over 2737 trades.

The stock hit an intraday high of Rs. 520.4 and intraday low of 502.05. The net turnover during the day was Rs. 25011677.

Source : Equity Bulls

Keywords